Are American Companies ‘Getting The Message’ About China Forced Labor?
The Congressional-Executive Committee on China says Temu, and even Nike, likely benefit from forced labor. Why the Uyghur Forced Labor law is vulnerable.
How Big Is Washington’s Appetite For Expanding Market Access For Farmers?
The House Ways & Means Committee hears from farmers who still say that, despite free trade deals with Mexico and Canada, some products still blocked.
House Ways & Means Tackles Critical Minerals for Biden’s Post-Fossil Fuels Economy
The U.S. has passed laws promoting the use of electric vehicles and battery manufacturing. But where will all the raw materials come from?
Government Incentives for Niche Sectors of Economy Leads to “Manufacturing Boom”
The recent spending on manufacturing facilities is almost entirely due to two pieces of legislation. That won’t be enough for a real, manufacturing boom.
May Trade Deficit Falls 7.3% to $68.9 Billion; China Deficit Drops 20%
The U.S. trade deficit remains on par to crack $1 trillion again. Meanwhile, a soft decoupling from China can be seen in the latest trade data.
Lighthizer: Raise Tariffs on Everything Made in China
The China tariffs, enacted by Lighthizer under Trump, are under review later this year. Will they stay or will they go? Lighthizer thinks they should stay…with more tariffs added.
Are Americans Investing in Chinese Forced Labor Companies?
The House Select Committee on the CCP published a preliminary report on the use of forced labor in Shein and Temu supply chains. Many Americans are investors.
Supply Chain Crisis, Not Tariffs, Stoked Inflation
Don’t blame the China tariffs on inflation. Supply chain snafus were a much bigger deal, a Federal Reserve report says.
Katherine Tai Says Globalization No Longer Sustainable
At National Press Club, Katherine Tai talks about supply chain issues, what ‘de-risking’ from China might look like, and how USTR thinks about it.
FDA Allows Uninspected China Lab to Sell Cancer Drugs in the US
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
